Outlook Therapeutics (OTLK) Invested Capital (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Invested Capital for 12 consecutive years, with $9.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital fell 17.96% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $90.5 million (down 13.54% YoY), while the FY2025 annual figure was $29.9 million, up 1.72% from the prior year.
• Invested Capital retreated to $9.8 million in Q1 2026 per OTLK's latest filing, from $36.7 million in the prior quarter.
• Across five years, Invested Capital topped out at $44.7 million in Q1 2024 and bottomed at $4267.0 in Q3 2023.
• Historically, Invested Capital has averaged $24.2 million across 5 years, with a median of $29.7 million in 2024.
• Annual changes were most pronounced in 2023 — Invested Capital tumbled 99.96% — and 2024, when it jumped 689846.1%.
• Outlook Therapeutics' Invested Capital stood at $10.9 million in 2022, then surged by 234.8% to $36.5 million in 2023, then declined by 15.87% to $30.7 million in 2024, then rose by 19.24% to $36.7 million in 2025, then tumbled by 73.15% to $9.8 million in 2026.
• Business Quant data shows OTLK's Invested Capital at $9.8 million in Q1 2026, $36.7 million in Q4 2025, and $29.9 million in Q3 2025.